Episodes
Tuesday Mar 26, 2024
Colon Cancer and CF: Panel (Video)
Tuesday Mar 26, 2024
Tuesday Mar 26, 2024
People with cystic fibrosis have 5-10 times the risk of developing colon cancer (25-30 times the risk post-transplant). Learn about the connection between colon cancer and CF, and the vital importance of early screening in this recorded webinar.
CFRI Executive Director, Siri Vaeth, was joined by community members Anna Payne, Thomas Horal, and Elyse Elconin-Goldberg, adults with CF who shared their personal experiences with colon cancer screening, prevention and diagnosis.
Tuesday Mar 26, 2024
Colon Cancer and CF: Panel (Audio)
Tuesday Mar 26, 2024
Tuesday Mar 26, 2024
People with cystic fibrosis have 5-10 times the risk of developing colon cancer (25-30 times the risk post-transplant). Learn about the connection between colon cancer and CF, and the vital importance of early screening in this recorded webinar.
CFRI Executive Director, Siri Vaeth, was joined by community members Anna Payne, Thomas Horal, and Elyse Elconin-Goldberg, adults with CF who shared their personal experiences with colon cancer screening, prevention and diagnosis.
Tuesday Mar 12, 2024
Recursos de asistencia a paciente
Tuesday Mar 12, 2024
Tuesday Mar 12, 2024
La guía integral de recursos de CFRI proporciona información sobre varios programas ofrecidos por nuestros socios. Escuche a Alicia Maciel, miembro de la comunidad de CFRI, mientras explica dónde encontrar y como utilizar la guía de recursos de asistencia al paciente de CFRI. Manténgase informado de cómo acceder a fuentes de apoyo financiero, asistencia de copagos para acceder a medicamentos, becas para personas con FQ y sus familiares, y mucho más.
Tuesday Mar 12, 2024
Cancer de Colon y Fibrosis Quistica
Tuesday Mar 12, 2024
Tuesday Mar 12, 2024
¿Sabía que las personas con FQ tienen entre 5 y 10 veces más probabilidades de desarrollar cáncer de colon?
Las personas con FQ tras un trasplante de pulmón tienen un riesgo entre 25 a 30 veces mayor, y los portadores de FQ también tienen más probabilidades de desarrollar cáncer de colon. Escuche a Alicia Maciel, miembro de la comunidad de CFRI, hablar sobre la hoja informativa del cáncer de colon. Conozca los riesgos y hable con su médico hoy sobre la prevención.
Tuesday Feb 20, 2024
Diversity, Equity and Inclusion in Cystic Fibrosis
Tuesday Feb 20, 2024
Tuesday Feb 20, 2024
CF impacts people of every race and ethnicity. Due to the misperception of CF as a disease impacting only those of European descent, many individuals go years without a diagnosis. In this moving film, CF community members share their experiences and their commitment to advocating for increased awareness on diversity, equity and inclusion among the CF and general population.
CFRI’s Faces of CF Diversity and Inclusion Program is sponsored by Vertex Pharmaceuticals, Viatris, Gilead Sciences, Chiesi USA, and Genentech, with additional translation support provided by Genentech.
Tuesday Jan 02, 2024
Tuesday Jan 02, 2024
Dr. Stephen Aller, Associate Professor at the Department of Pharmacology and Toxicology at the University of Alabama in Birmingham, presents results from CFRI-funded research on the role of CFTR Arginine-933 in FDA-approved drug potentiation. His team used cryo-electron microscopy (cryo-EM) to visualize high-quality structures with limited quantities of purified CFTR. This presentation was part of CFRI's 36th National CF Education Conference.
CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.
Tuesday Jan 02, 2024
Tuesday Jan 02, 2024
Dr. Stephen Aller, Associate Professor at the Department of Pharmacology and Toxicology at the University of Alabama in Birmingham, presents results from CFRI-funded research on the role of CFTR Arginine-933 in FDA-approved drug potentiation. His team used cryo-electron microscopy (cryo-EM) to visualize high-quality structures with limited quantities of purified CFTR. This presentation was part of CFRI's 36th National CF Education Conference.
CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.
Tuesday Jan 02, 2024
Tuesday Jan 02, 2024
Dr. Kenichi Okuda, a Research Associate at Marsico Lung Institute at University of North Carolina at Chapel Hill, presents results from CFRI-funded research on pathways maintaining basal mucin and CFTR-mediated fluid secretion in the human distal airway. He argues that airway cells are a therapeutic target for molecular therapy for CFTR function restoration. This presentation was part of CFRI's 36th National CF Education Conference.
CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.
Tuesday Jan 02, 2024
Tuesday Jan 02, 2024
Dr. Kenichi Okuda, a Research Associate at Marsico Lung Institute at University of North Carolina at Chapel Hill, presents results from CFRI-funded research on pathways maintaining basal mucin and CFTR-mediated fluid secretion in the human distal airway. He argues that airway cells are a therapeutic target for molecular therapy for CFTR function restoration. This presentation was part of CFRI's 36th National CF Education Conference.
CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.
Tuesday Nov 21, 2023
Tuesday Nov 21, 2023
Dr. Ahmet Uluer, a medicine and pediatric trained pulmonologist and Director of the Adult Cystic Fibrosis Program at the combined Boston Children’s Hospital and Brigham & Women’s Hospital Adult Cystic Fibrosis Center, gives an overview of the impact of and risk associated with aging for people with CF, including GI cancers, complications associated with diabetes, hypertension, bone disease, hearing loss, kidney disease, cardiovascular disease, among others.
Anna Payne, a 36 year-old woman living with CF and colon cancer, shares the real-life impact that colon cancer has on people and what it is like to live with two diseases. Diagnosed at 34 - well before the recommended screening age of 40 – she is now seeking to educate others about the elevated risk that CF patients and carriers have of developing colon cancer. This joint presentation was part of CFRI's 36th National CF Education Conference.
CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.